Orphan Star Therapeutics is a NYC-based biopharmaceutical company focused on developing innovative therapies for rare genetic diseases. Its core work centers on building an early-stage pipeline of drug candidates for rare neurometabolic diseases, including a program targeting Canavan disease. The company intends to advance these early-stage candidates using a newly secured $20M commitment from an unnamed commercial pharmaceutical partner. Orphan Star also plans to complement its pipeline by acquiring or partnering for promising clinical-stage drug candidates through strategic industry and academic collaborations. Leadership is headed by founder and CEO Dr. Nick France. Recent team additions include Adam Simpson, PhD, as Head of Business Development and Katie St. Ledger as Senior Director of Clinical Research and Development, reflecting an operational buildout. The company has added Scientific Advisory Board members Professor Paola Leone and Prof. Dr. Alex Veldman to support development in Canavan disease and pediatric drug development.

Total raised

$20M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2018